Immatics N.V.: Vestal Point Capital, LP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Vestal Point Capital, LP disclosed a stake of more than 5% in Immatics N.V. via a Schedule 13G filing with the SEC (accession 0000902664-26-004576). The exact share count and percentage were not specified in the headline disclosure. The filing signals that Vestal Point has crossed the 5% passive-investor threshold in the clinical-stage biotech. Investors will watch for further detail on the position size and any subsequent 13G amendments.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Vestal Point Capital, LP, Immatics N.V.